Genital Herpes - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Genital Herpes - Pipeline Review, H2 2016

Genital Herpes - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Genital Herpes - Pipeline Review, H2 2016
Published Aug 10, 2016
107 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Genital Herpes - Pipeline Review, H2 2016, provides an overview of the Genital Herpes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Genital Herpes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Herpes
- The report reviews pipeline therapeutics for Genital Herpes by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Genital Herpes therapeutics and enlists all their major and minor projects
- The report assesses Genital Herpes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Genital Herpes

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Genital Herpes
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
- Develop an

  
Source:
Document ID
GMDHC8338IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Genital Herpes Overview101
Therapeutics Development112
  Pipeline Products for Genital Herpes Overview111
  Pipeline Products for Genital Herpes Comparative Analysis121
Genital Herpes Therapeutics under Development by Companies132
Genital Herpes Therapeutics under Investigation by Universities/Institutes151
Genital Herpes Pipeline Products Glance162
  Clinical Stage Products161
  Early Stage Products171
Genital Herpes Products under Development by Companies181
Genital Herpes Products under Investigation by Universities/Institutes191
Genital Herpes Companies Involved in Therapeutics Development2021
  Admedus Ltd201
  Agenus, Inc.211
  AiCuris GmbH &Co. KG221
  Foamix Pharmaceuticals Ltd.231
  Genocea Biosciences, Inc.241
  GenVec, Inc.251
  Immune Design Corp.261
  JN-International Medical Corporation271
  Mymetics Corporation281
  NanoBio Corporation291
  NanoViricides, Inc.301
  PaxVax, Inc.311
  Profectus BioSciences, Inc.321
  Redbiotec AG331
  Sanofi Pasteur SA341
  Shulov Innovative Science Ltd.351
  Starpharma Holdings Limited361
  Tomegavax, Inc.371
  Vaccibody AS381
  Vaxart, Inc.391
  Vical Incorporated401
Genital Herpes Therapeutics Assessment419
  Assessment by Monotherapy Products411
  Assessment by Target422
  Assessment by Mechanism of Action442
  Assessment by Route of Administration462
  Assessment by Molecule Type482
Drug Profiles5040
  acyclovir Drug Profile501
  Aspidasept Drug Profile511
  astodrimer Drug Profile524
  G-103 Drug Profile561
  GEN-002 Drug Profile571
  GEN-003 Drug Profile584
  genital herpes (virus like particle) vaccine Drug Profile621
  genital herpes vaccine Drug Profile632
  genital herpes vaccine Drug Profile652
  genital herpes vaccine Drug Profile671
  genital herpes vaccine Drug Profile681
  genital herpes vaccine Drug Profile691
  GV-2207 Drug Profile701
  herpes simplex virus [type 1, 2] vaccine Drug Profile711
  herpes simplex virus [type 1, 2] vaccine Drug Profile721
  herpes simplex virus 2 vaccine Drug Profile731
  herpes simplex virus 2 vaccine Drug Profile741
  herpes simplex virus 2 vaccine Drug Profile751
  herpes simplex virus 2 vaccine Drug Profile761
  herpes simplex virus 2 vaccine Drug Profile771
  herpes simplex virus 2 vaccine Drug Profile781
  HSV-529 Drug Profile792
  pritelivir Drug Profile812
  Small Molecule for Genital Herpes Drug Profile831
  VCLHB-01 Drug Profile842
  VCLHM-01 Drug Profile862
  ZEP-3 Drug Profile882
Genital Herpes Dormant Projects902
Genital Herpes Discontinued Products921
Genital Herpes Product Development Milestones9313
  Featured News &Press Releases931
    Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits931
    Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016931
    Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing941
    Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging951
    Feb 03, 2016: Model helps decide drug dose for clinical testing961
    Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003961
    Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003971
    Sep 22, 2015: NanoBio's Genital Herpes Vaccine Demonstrates Efficacy In Guinea Pigs As Both A Prophylactic And A Therapeutic Vaccine981
    Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo on Vaccines and Vaccination in Birmingham, UK on August 18, 2015991
    May 20, 2015: Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003991
    Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing commences1001
    Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes1011
    Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For Its Intranasal Vaccine To Protect Against Genital Herpes Infection1021
    Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation1031
    Nov 07, 2013: Agenus HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial1042
Appendix1062
  Methodology1061
  Coverage1061
  Secondary Research1061
  Primary Research1061
  Expert Panel Validation1061
  Contact Us1061
  Disclaimer1071

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Genital Herpes - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Genital-Herpes-Pipeline-Review-H2-2016-2088-16346>
  
APA:
Global Markets Direct - Market Research. (2016). Genital Herpes - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Genital-Herpes-Pipeline-Review-H2-2016-2088-16346>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.